Duloxetine in Inflammatory Bowel Diseases

This open-label, prospective, single-arm pilot study investigates the use of duloxetine, a central neuromodulator, for improving psychological distress and functional impairment in adults with inflammatory bowel disease (IBD). The study focuses on patient-reported outcomes related to anxiety, depression, and IBD-related disability, aiming to assess feasibility, tolerability, and preliminary efficacy in modulating gut-brain axis symptoms and disease-related functional impairments in life

NCT Number	NCT07431606
Lead Sponsor	University of Pennsylvania
Conditions	Inflammatory Bowel Diseases
Enrollment	32 participants
Start Date	2026-05-01
Primary Completion	2027-03-01 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-16